Therapy-related myeloid neoplasms
Help me code for diagnosis year :
AML occurs after autologous bone marrow and stem cell transplantation; patients over 40 years at transplant who receive total body irradiation are at highest risk.
Therapy-related AML can result from chemotherapy or radiation therapy for benign or malignant diseases. Treatment options are the same as for other myelodysplastic syndromes.
In the 2008 WHO Manual, this code also includes therapy-related Myelodysplastic syndrome (t-MDS) and myelodysplastic/myeloproliferative neoplasms (t-MDS-MPN) occurring as late complications of prior cytotoxic chemotherapy and/or radiation therapy administered for a neoplastic or non-neoplastic disorder. Peripheral blood and bone marrow are the principle sites of involvement.
Although WHO groups therapy-related Myelodysplastic sydrome with the therapy-related AML MDS, MPN, and MDS-MPN, the ICD-O-3 has a separate code for therapy-related MDS 9987/3. WHO has grouped these therapy-related myeloid neoplasms into one category because current clinical practice recognizes these neoplasms as being similar in etiology (therapy-related) and groups them for the purpose of analysis. Therapy-related myeloid neoplasms represent coincidental disease and would be expected to behave like other de-novo disease.
For those cases diagnosed 2010 and later, Therapy-related myelodysplasic syndrome, NOS should be coded to the 9920/3 category.
DO NOT code therapy-related myeloid neoplasm simply because the patient has a history of radiation therapy or chemotherapy. There must be a physician's statement that says this is a therapy-related neoplasm (acute myeloid leukemia, MDS, MPN, or MDS/MPN.)
If a specific myeloid neoplasm that is described with a different specific histology term is also stated to be therapy related, code 9920/3 to capture the fact that this disease was therapy related. Document the other specific histology term in the text part of the abstract.